Company news
Argent Biopharma Ltd news in 2026
Argent Biopharma Ltd's news releases, calls and decks from 2026, newest first.
RGT Executes Global Licence for Non-Core Cannabis Genetics
October 26, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 22, 2026
Notice of Annual General Meeting/Proxy Form
October 18, 2026
Date of AGM and Closing Date for Director Nominations
October 14, 2026
Strategic Focus on Immune Modulation and Longevity
October 11, 2026
Application for quotation of securities - RGT
October 2, 2026
Execution of Loan Facility Agreement
September 30, 2026
Argent Signs NLC Licence to Expand Antiviral Portfolio
September 28, 2026
Proposed issue of securities - RGT
September 28, 2026
Notification of cessation of securities - RGT
September 1, 2026
Appendix 4E and 2026 Annual Report
August 31, 2026
Appendix 4G and Corporate Governance Statement
August 31, 2026
FDA-CVM Establish INAD File for CannEpil Veterinary Program
August 25, 2026
Proposed issue of securities - RGT
August 10, 2026
$250,000 in Funding Received under Financing Facility
August 10, 2026
US Veterinary Development Programme for CannEpil Commences
August 5, 2026
Notification of cessation of securities - RGT
August 3, 2026
CannEpil Global Licence Expands into Veterinary Healthcare
July 30, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
July 27, 2026
RGT Executes Global CannEpil Licensing Deal for US$5.5M
July 6, 2026
Half Yearly Report and Accounts
February 27, 2026
Provisional Patent Lodged with USPTO for NanoBodies Platform
February 24, 2026
CannEpil - Largest Commercial Shipment Arrives in Ireland
February 22, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Streamlined Acquisition of AusCann Assets
January 13, 2026